Trial Profile
Relative Bioavailability of a Single Oral Dose of BI 113823 (50 mg qd) When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole (200 mg Bid) in Healthy Male Volunteers (an Open Label, Two Periods, Fixed-sequence, Clinical Phase I Study).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2013
Price :
$35
*
At a glance
- Drugs BI 113823 (Primary) ; Ketoconazole
- Indications Osteoarthritis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 23 Oct 2010 New trial record